Status:
COMPLETED
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Lead Sponsor:
Karo Bio AB
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has in clinical tria...
Eligibility Criteria
Inclusion
- Males or females aged 18 to 75 years
- Patient with primary hypercholesterolemia with an LDL-cholesterol \> 3.0 mmol/L
- At randomization, diet as instructed by the investigator during the last 4 weeks prior to randomization and willingness to follow these instructions throughout the study
Exclusion
- History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00677248
Start Date
April 1 2008
End Date
October 1 2008
Last Update
December 1 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karo Bio AB
Huddinge, Sweden